[Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].
Paradoxical bleedings are complications occurring under replacement therapy in haemophiliacs by disturbancies of the primary haemostasis. They have been observed during treatment with factor-VIII- and prothrombin-complex concentrates of long duration and in high dosage. Clinical complications, for example delayed wound healing as well as spontaneous bleedings into the skin and from the mucous membranes, have been observed in one quarter of haemophiliacs under substitution therapy. In one third of these patients pathological parameters of primary haemostasis (prolonged bleeding time, reduced retention, retraction, ADP- and collagen-induced aggregation and the platelet factor 3 release) were found out. The following mechanisms or substances may be the cause for these disturbancies: 1. fibrinogen and factor-VIII split products 2. high content of proteins predominantly fibrinogen and factor-VIII-related antigen 3. antigen-antibody reactions 4. development of inhibitors against the Willebrand factor. For treatment of the paradoxical bleedings freshly prepared cryoprecipitate, prednison and Etamsylatum have been used.
Sutor
A H
AH
Universitäts-Kinderklinik Freiburg.
D000925:Anticoagulants / Q000097:blood; D001760:Bleeding Time; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D005164:Factor IX / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII / Q000009:adverse effects* / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology*; D006487:Hemostasis; D006801:Humans; D010974:Platelet Aggregation; D014945:Wound Healing; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D014841:von Willebrand Factor; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX
Paradoxe Blutung als Komplikation der Hämophilie-Behandlung mit Faktor-VIII- bzw. Faktor-IX-Präparaten.